Last reviewed · How we verify
NCT05645263
Coca-cola's Clinical Effects on Gastric Phytobezoars
NA trial testing dieting Coca-cola in Bezoars in 492 participants. Completed in 31 December 2021.
31 December 2020
Quick facts
| Lead sponsor | The Affiliated Hospital of Qingdao University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 492 |
| Start date | 1 January 2017 |
| Primary completion | 31 December 2020 |
| Estimated completion | 31 December 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- dieting Coca-cola
Conditions studied
- Bezoars — all drugs for Bezoars →
Sponsor
The Affiliated Hospital of Qingdao University
Who can join
12 and older, any sex, with Bezoars. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Consecutive patients suffering from gastric phytobezoars were divided into 3 groups (Group 1, Group 2 and Group 3) according to the phytobezoars' formation time and each group was further subdivided into control and intervention group according to whether Coca-Cola was admitted. All patients in intervention group dieted Coca-Cola whereas patients in control group refused to drink Coca-Cola and had willing to receive the emergently gastric fragmentation.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Coca-Cola consumption <i>vs</i> fragmentation in the management of patients with phytobezoars: A prospective randomized controlled trial.
Liu FG, Meng DF, Shen X, Meng D, et al · · 2024 · cited 5× · PMID 38464817 · DOI 10.4253/wjge.v16.i2.83
Verify or expand the search:
- PubMed search for NCT05645263
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other The Affiliated Hospital of Qingdao University trials
Trials by the same sponsor.
- NCT07485920 — A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedani · Phase 4 · not yet recruiting
- NCT07465861 — Bed Rest Duration and Outcomes in Endoscopic Skull Base Reconstruction · NA · not yet recruiting
- NCT07453771 — Safety and Efficacy of Small Extracellular Vesicles Nebulizer in Patients With Allergic Rhinitis Complicated With Asthma · NA · not yet recruiting
- NCT07404709 — Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Ste · Phase 1, PHASE2 · not yet recruiting
- NCT07167342 — The Effect of Oral Clostridium Butyricum on the Recurrence After Colonoscopic Resection of Colorectal Adenoma · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05645263 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Affiliated Hospital of Qingdao University
- Last refreshed: 9 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05645263.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing